Myositis and myasteniform syndrome related to pembrolizumab

This case report concerns a 63-year-old man affected by metastatic undifferentiated liposarcoma. After receiving pembrolizumab as a second-line treatment in a clinical trial, the patient experienced an immune-mediated myocarditis, myositis and myasteniform syndrome. The last two adverse events showe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Case Rep
Main Authors: Sanchez-Sancho, Pablo, Selva-O'Callaghan, Albert, Trallero-Araguás, Ernesto, Ros, Javier, Montoro, Bruno
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8296758/
https://ncbi.nlm.nih.gov/pubmed/34290006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-241766
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados